REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

December 2, 2020

Study Completion Date

October 22, 2021

Conditions
Acute Respiratory FailureCOVID-19TraumaStrokeSepsisShock
Interventions
DRUG

Remimazolam

Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.

Trial Locations (1)

Unknown

CHU de Nantes, Nantes

All Listed Sponsors
collaborator

Paion UK Ltd.

INDUSTRY

lead

Nantes University Hospital

OTHER

NCT04611425 - REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study | Biotech Hunter | Biotech Hunter